Inspire Pharmaceuticals news from FierceBiotech
NewsInspire Pharma shares soar 75% on CF data
Shares of Durham, NC-based Inspire Pharmaceuticals took off this morning after researchers announced that a late-stage trial of its cystic fibrosis therapy produced promising results. Patients taking Read more...
Inspire abandons nasal spray after drug flunks trial
Disappointed by lackluster data, Inspire Pharmaceuticals has abandoned development of its epinastine nasal spray for the treatment of seasonal allergic rhinitis. Subjects treated with the nasal Read more...
C&L: Ellis joins Atrolyn Biosciences as CEO
M. Nixon Ellis, Ph.D. has joined Argolyn Bioscience as president and CEO and George Koszalka, Ph.D. has become the company's chief development officer. TOPIGEN Pharmaceuticals announced that Paul Read more...
Inspire bails on $89M allergy pact
A little more than a year after Read more...
Inspire gets $75M injection from Warburg Pincus
Warburg Pincus is buying $75 million worth of Inspire Pharmaceuticals' stock. The private Read more...
DEALS: Abbott buys Kos in $3.7B deal
FAES inks $89M licensing deal on allergy drugInspire Pharmaceuticals has agreed to pay Spain's FAES Farma $7 million up front and up to $82 million in milestone payments for the U.S. and Canadian licensing rights to bilastine. The drug is currently in Phase III for allergic rhinitis, a seasonal allergic reaction that includes runny nose. Faes will also receive royalties on sales. "Based on the clinical profile to date, we believe that the oral formulations of … Read more...ALSO NOTED: Wyeth bullish on late-stage drug; Zeltia forms research arm; and much more...> Wyeth is bullishly forecasting potential annual sales of the experimental drug bazedoxifene after analyzing late-stage data for osteoporosis and vasomotor symptoms of menopause. Report > Wyeth has inked a $195 million licensing pact with the UK's Biotica for novel rapamycin analogs. … Read more...Side effects prompt Inspire to shutter trialInspire Pharmaceuticals announced that it shuttered a mid-stage drug trial on the recommendation of its data monitoring committee after seeing data on a "range of bleeding complications among volunteers. There were no deaths reported among the 160 participants in the trial, who were taking the experimental INS50589 Antiplatelet after undergoing coronary artery bypass graft surgery utilizing a cardiopulmonary bypass pump. The company said it would undertake a thorough review of what … Read more...ALSO NOTED: Nektar closes UK site; Martines resigns from NSP; and much more...> Nektar Therapeutics has closed a site in the U.K. that employs 35 workers. Report > Chutes & Ladders: Sergio Martines has resigned as a director, president and CEO of NSP Pharma. Release > Inspire Pharmaceuticals has launched a Phase III clinical … Read more... | Press ReleasesInspire Pharmaceuticals to Discontinue Development of Epinastine Nasal Spray Inspire Pharmaceuticals to Discontinue Development of Epinastine Nasal Spray 4/23/2008 DURHAM, N.C. -- Inspire Pharmaceuticals announced today that its Phase 3 trial with epinastine nasal spray for Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets